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Abstract
Background: Patients with amyotrophic lateral sclerosis (ALS) suffer from hypoventilation, which can easily worsen during
sleep. This study evaluated the efficacy of capnography monitoring in patients with ALS for assessing nocturnal
hypoventilation and predicting good compliance with subsequent noninvasive ventilation (NIV) treatment.
Methods: Nocturnal monitoring and brief wake screening by capnography/pulse oximetry, functional scores, and other
respiratory signs were assessed in 26 patients with ALS. Twenty-one of these patients were treated with NIV and had their
treatment compliance evaluated.
Results: Nocturnal capnography values were reliable and strongly correlated with the patients’ respiratory symptoms
(R
2=0.211–0.305, p=0.004–0.021). The duration of nocturnal hypercapnea obtained by capnography exhibited a significant
predictive power for good compliance with subsequent NIV treatment, with an area-under-the-curve value of 0.846 (p=0.018).
In contrast, no significant predictive values for nocturnal pulse oximetry or functional scores for nocturnal hypoventilation were
found. Brief waking supine capnography was also useful as a screening tool before routine nocturnal capnography monitoring.
Conclusion: Capnography is an efficient tool for assessing nocturnal hypoventilation and predicting good compliance with
subsequent NIV treatment of ALS patients, and may prove useful as an adjunctive tool for assessing the need for NIV
treatment in these patients.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a common neurodegener-
ative disease of adults with a prevalence of about 6 in 100,000. Most
patients with ALS have progressive hypoventilation due to
respiratory muscle weakness [1], which is associated with poor
survival, cognitive impairment, and poor quality of life [2,3,4,5].
Hypoventilation in these patients can easily worsen during sleep as a
result of sleep-disordered breathing (apnea and hypopnea), hypoto-
nia of the accessory respiratory muscles, weak diaphragm, supine
position (orthopnea), and a possible dysfunction of the central drive
for respiration [2,5]. Nocturnal pulse oximetry monitoring, which is
widely accepted to be an important screening tool for assessing the
degree of nocturnal hypoventilation and the need for noninvasive
ventilation (NIV) in patients with ALS [6,7,8,9], assesses the
oxygenation status rather than the ventilation status of patients. As
such, it may not be sufficiently sensitive to detect nocturnal
hypoventilation or to reveal the need for ventilatory support.
Capnography is a simple and noninvasive tool that enables the
indirect but continuous monitoring of ventilatory status by
measuring the end-tidal carbon dioxide (ETCO2) levels in the
expired air [10]. It has been validated as a reliable screening
method for sleep apnea syndromes [11] and an indicator of
arterial partial pressure of carbon dioxide (PaCO2) in most
spontaneously breathing adult patients [12], and it is strongly
correlated with transcutaneous carbon dioxide (tcCO2) data in
pediatric patients with sleep-disordered breathing [13].
The aim of this study was to determine the efficacy of capnography
monitoring for assessing nocturnal hypoventilation and for predicting
compliance with subsequent NIV treatment in ALS patients.
Methods
1. Patients
This study was conducted at the Seoul National University ALS
clinic between March 2006 and July 2009. Twenty-six patients (19
males) with either definite or probable ALS [14] who had
subjective symptoms associated with hypoventilation (orthopnea,
dyspnea on exertion, daytime drowsiness, morning headache,
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(unrefreshing sleep, or sleep fragmentation due to shortness of
breath) or decreased vital capacity (,80% of normal) were studied
[15,16]. Exclusion criteria were a pulmonary disease at inclusion,
including pneumonia, history of NIV treatment or oxygen
supplementation, or a tracheostomy at inclusion [12,17,18].
(Table 1). This study was approved by the institutional review
board (IRB) of Seoul National University Hospital, and written
informed consent was obtained from all participants.
2. Parameters
Capnography (CO2SMO, Respironics Novametrix, Walling-
ford, CT, USA) with a nasal prong [11] was used to measure the
duration of nocturnal hypercapnea during sleep (defined as the
percentage of the total sleep time when ETCO2.47 mmHg) [19].
the average ETCO2 during sleep, and the maximal nocturnal
ETCO2. Pulse oximetry (CO2SMO, Respironics Novametrix)
was used to measure the duration of nocturnal hypoxia during
sleep (assessed both as the percentage of the total sleep time when
arterial oxygen saturation, SaO2, ,90% and when SaO2,95%)
[3,7], the average pulse oximetry level, and the minimal nocturnal
SaO2. Nocturnal vital signs, such as respiration rate and pulse
rate, were also measured with capnography and pulse oximetry.
Daytime arterial blood gas analysis while in the supine position,
disease severity, and the degree of respiratory difficulty (ALS
Functional Rating Scale–Revised, ALSFRSr) were also analyzed
[20]. Analysis of the presence and severity of hypercapnea during
sleep in patients with ALS was performed using NovaCARD
software (Respironics Novametrix). Brief waking supine monitor-
ing of capnography and oximetry were also performed while the
patients were in a supine position for more than 10 min. Scores on
a nocturnal-orthopnea questionnaire as part of the ALSFRSr were
used as measures of symptoms of nocturnal hypoventilation, and
sums of ALSFRSr scores for ‘speech’, ‘salivation’, and ‘swallowing’
as part of the ALSFRSr were used as measures of bulbar function
[20].
3. NIV treatment
After obtaining informed their consent to participate, patients
who had orthopnea [8] or who met the published criteria of Leigh
et al. [16] were offered NIV in the hospital during admission,
Table 1. Baseline characteristics of the amyotrophic lateral sclerosis (ALS) patients.
Demographics
n 26
Age, years 53.9269.83 (38–74)
Males:females 19:7
ALSFRSr 32.0068.85 (20–47)
Disease duration, months 24.5168.10 (8.10–49.5)
VC, % predicted 57.19627.71 (8–104)
Respiratory symptoms, n (%)
Orthopnea 21 (80.77%)
Daytime drowsiness 21 (80.77%)
Dyspnea on exertion 18 (69.2%)
Subjective sleep fragmentation due to shortness of breath 3 (11.5%)
ABGA
pH 7.4160.04 (7.306–7.47)
PaCO2, mmHg 45.43610.62 (36.6–83.8)
PaO2, mmHg 92.81619.22 (61.2–130)
HCO3
–, mmol/l 27.2963.89 (24.0–41.0)
SaO2,% 96.4161.73 (93.1–99.2)
Severity of nocturnal hypercapnea/hypoxia
Percentage of total sleep time with ETCO2.47 mmHg 16.55631.04 (0–93.98)
Maximal nocturnal ETCO2, mmHg 54.32612.57 (38–84)
Average nocturnal ETCO2, mmHg 42.0769.01 (23–63.91)
Percentage of total sleep time with SaO2,90% 8.98621.08 (0–94.29)
Minimal nocturnal SaO2,% 80.20619.32 (1–93)
Average nocturnal SaO2,% 94.4963.03 (84.04–97)
Bulbar function
Bulbar subscores in ALSFRSr 5.7762.20 (0–8)
Patients with severe bulbar dysfunction, number (percent) 4, (15.4%)
Compliance with NIV, hours/day (applied in 21 patients)
4.7462.93 (0–10)
Except where stated otherwise, data are expressed as mean6standard deviation (range) values. ALSFRSr, ALS Functional Rating Scale-Revised; ABGA, arterial blood gas
analysis; ETCO2, end-tidal carbon dioxide; NIV, noninvasive ventilation; VC, vital capacity; SaO2, arterial oxygen saturation; PaO2, arterial partial pressure of oxygen;
PaCO2, arterial partial pressure of carbon dioxide.
doi:10.1371/journal.pone.0017893.t001
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Vitalaire, Italy). Titration of NIV was achieved during admission
as follows: initial low NIV pressure [inspiratory positive-airway
pressure/expiratory positive-airway pressure (IPAP/EPAP) of 8/
4 cmH2O] in the S/T mode was used to adjust the NIV, and then
the NIV and IPAP/EPAP were titrated until respiratory symptoms
(dyspnea or orthopnea) disappeared and/or a tidal volume of 10–
15 ml/kg [21] was delivered to patients in a comfortable
condition.
T h ed e g r e eo fc o m p l i a n c ew i t ht h eN I Vt r e a t m e n tw a sd e f i n e d
according to the mean NIV use per day and assessed in the outpatient
clinic or at the patient’s home at 1 month after treatment [8].
According to previous studies, good compliance with NIV treatment
can be defined as NIV use for more than 4 hours per day [22,23].
4. Statistical analysis
Linear regression analysis and nonparametric receiver operating
characteristic (ROC) curve statistical analyses were performed
with Predictive Analytics Software (version 18); a significance level
of p,0.05 was used throughout.
Results
1. Clinical and demographic characteristics
The age, respiratory symptoms and signs, disease severity, and
compliance with subsequent NIV treatment of the included
patients are given in Table 1.
2. Reliability of capnography and its correlation with
nocturnal hypoventilation symptoms
Nocturnal and waking supine ETCO2 data were obtain-
able in 25 patients, with the remaining one patient continuing
mouth breathing. Of those 25 patients, the waking supine
ETCO2 was strongly correlated with their PaCO2, implying
that capnography was a reliable screening tool for measuring
PaCO2 in our patients (Figure 1). Both nocturnal average
ETCO2 (Figure 2-A) and the duration of nocturnal hypercap-
nea (Figure 2-B) were strongly correlated with the severity of
nocturnal respiratory symptoms (orthopnea-questionnaire scores
from the ALSFRSr; Figure 2). However, the respiratory signs
among patients with the same orthopnea-questionnaire scores
varied markedly. For example, among patients with a score on
the orthopnea questionnaire of 3, the average ETCO2 ranged
from 33 to 61 mmHg (Figure 2-A) and the duration of nocturnal
hypercapnea ranged from 0% to 87% of the total sleep time
(Figure 2-B), which means that our assessment of subjective
nocturnal respiratory symptoms may not have been sufficiently
sensitive to reflect the actual degree of nocturnal hypoventila-
tion or the need for ventilatory support in these patients
(Figure 2).
3. Prediction of good compliance with subsequent NIV
treatment with nocturnal respiratory signs, respiratory
symptoms, and bulbar function
ROC curve analysis revealed good predictive values for
compliance with subsequent NIV treatment for the duration of
nocturnal hypercapnea (ETCO2.47 mmHg) and average noc-
turnal ETCO2, with area-under-the-curve values of 0.846 and
0.853, respectively. However, no significant findings were obtained
in this regard for the duration of nocturnal hypoxia, average level
of nocturnal SaO2, and ALSFRSr scores for orthopnea and bulbar
function (Figure 3, Table 2, Figure S1). The duration of nocturnal
hypercapnea during sleep had a sensitivity of 78.6% and a
specificity of 83.3% for predicting good compliance with sub-
sequent NIV treatment with a cut-off value of more than 1% of the
total sleep time, and had a sensitivity of 50% and a specificity of
100% with a cut-off value of more than 5% of the total sleep time
(Table S1).
Figure 1. The average level of end-tidal carbon dioxide (ETCO2) measured by waking supine capnography correlated significantly
with arterial partial pressure of carbon dioxide (PaCO2) level, as measured by arterial blood gas analysis (p,0.001).
doi:10.1371/journal.pone.0017893.g001
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monitoring as a screening tool for hypoventilation
While nocturnal capnography is a simple method of measuring
nocturnal respiratory insufficiency, it requires continuous over-
night monitoring. Thus, we also evaluated the efficacy of shorter-
duration daytime waking supine capnography monitoring (mean
duration, 20.58 min). The average level of waking supine ETCO2
was significantly correlated with the duration of nocturnal
hypercapnea and nocturnal respiratory symptoms in our patients
(Figure 4). ROC curve analysis revealed a high diagnostic power of
average ETCO2 level measured by waking supine capnography
screening as a predictor of good compliance with subsequent NIV
treatment, but not of SaO2 measured by waking supine pulse
oximetry screening (Figure 5). With a cut-off mean ETCO2 value
of more than 39.50 mmHg, the brief waking capnography
screening exhibited a sensitivity of 69.2% and a specificity of
83.3% for predicting good compliance with subsequent NIV
treatment (Table S2).
Figure 2. Correlations between nocturnal respiratory symptoms (orthopnea) with respiratory monitoring results. Scores from
orthopnea questionnaire were strongly correlated with the average level of ETCO2 (R
2=0.305, p=0.004) (A) and the duration of hypercapnea
measured by nocturnal capnography (R
2=0.211, p=0.021) (B).
doi:10.1371/journal.pone.0017893.g002
Figure 3. Receiver operating characteristic (ROC) curve for the
duration of nocturnal hypercapnea relative to the total sleep
time (ETCO2.47%) and the average nocturnal ETCO2 level (avr
ETCO2) as predictors of good compliance with subsequent
noninvasive ventilation (NIV) treatment. The areas under the
curve (AUCs) were 0.846 (95% confidence interval, CI: 0.628–1.000) and
0.856 (95% CI: 0.00–1.000), respectively.
doi:10.1371/journal.pone.0017893.g003
Table 2. Receiver operating characteristic (ROC) curve
analysis for parameters obtained by monitoring with
nocturnal capnography and pulse oximetry, scores on an
orthopnea questionnaire, and scores on a bulbar-function
questionnaire as predictors of good compliance with
subsequent NIV treatment.
Parameter AUC p
95% Confidence
interval
Duration for ETCO2.47 mmHg 0.846 0.018 0.628–1.000
Average ETCO2 0.853 0.016 0.000–1.000
Duration for SaO2,95% 0.596 0.511 0.328–0.864
Average SaO2 0.417 0.569 0.147–0.687
Orthopnea questionnaire 0.218 0.054 0.000–0.466
Bulbar-function questionnaire 0.429 0.630 0.125–0.734
AUC: area under the curve.
doi:10.1371/journal.pone.0017893.t002
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We have shown herein that capnography can reflect PaCO2
level reliably, that it is strongly correlated with nocturnal
respiratory symptoms and, moreover, that it is highly predictive
of good compliance with subsequent NIV treatment in selected
patients with ALS. In addition, brief waking supine capnography
can be useful as a screening tool for nocturnal hypoventilation and
compliance with subsequent NIV treatment.
Early detection and correction of hypoventilation is important
in patients with ALS, because it can slow disease progression and
improve cognitive function and quality of life [3,4,5,8,24].
However, because NIV treatment that is initiated too early can
cause poor compliance due to discomfort in some patients [8], and
since patients with ALS can benefit only from sufficient use of NIV
(NIV compliance .4 hours/day) [23], correctly selecting patients
who are really in need of NIV treatment is also important.
Several previous studies that investigated the efficacy of
measuring ETCO2 as an indicator of PaCO2 found that it can
only be accepted as an accurate predictor of PaCO2 when the
following clinical characteristics apply [11,12,17,18,22]:
1. Intubated patients [17].
2. Spontaneously breathing (nonintubated) patients without
significant dead space in the lung [18,25], NIV use, or oxygen
supplements [12].
3. ETCO2 recorded with a nasal prong and not with a
nasobuccal mask, which might lower the diagnostic sensitivity
in patients with severe respiratory symptoms [11].
By including only patients conforming with the above
conditions we showed that ETCO2 monitoring can be useful in
selected patients with ALS.
The presence of nocturnal respiratory or sleep-related symp-
toms can be a good indication for initiating NIV in patients with
ALS [8]. However, as shown in the present study, measurement of
ETCO2 by capnography monitoring is another good supportive
indication for NIV, and has a higher predictive power for
identifying patients who are likely to comply well with subsequent
NIV treatment than either pulse oximetry monitoring or
assessment of subjective symptoms with ALSFRSr (Table 2).
The orthopnea part of the ALSFRSr assesses symptoms for
nocturnal respiratory difficulty and is graded as follows: 0, unable
to sleep; 1, can only sleep sitting up; 2, needs extra pillows (more
than two) in order to sleep; 3, some difficulty in sleeping at night
due to shortness of breath, does not routinely use more than two
pillows; and 4, no orthopnea during sleep [20]. However, ‘some
Figure 4. The average ETCO2 level obtained with brief wake capnography screening (wake avr ETCO2) correlated significantly with
symptoms of patients for nocturnal hypoventilation (orthopnea; p=0.021) (A) and duration of nocturnal hypercapnea relative to
the total sleep time (nocturnal ETCO2.47%; p,0.001) (B).
doi:10.1371/journal.pone.0017893.g004
Figure 5. ROC curves for average ETCO2 measured by wake
capnography screening and average SaO2 measured by wake
pulse oximetry screening as predictors of good compliance
with subsequent NIV treatment. The AUC values were 0.840 (95%
CI: 0.628–1.000) and 0.192 (95% CI: 0.000–0.389), respectively.
doi:10.1371/journal.pone.0017893.g005
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subjective and vague, so that patients with various degrees of
respiratory signs can be included in this category, as was the case
in our study (Figure 2). In addition, some patients with ALS prefer
the decubitus position rather than elevating their head with extra
pillows to compensate for their nocturnal hypoventilation [26],
which implies that the number of pillows alone might not be a
sensitive indicator for the degree of nocturnal hypoventilation.
While pulse oximetry has been widely used as a screening tool
for nocturnal hypoventilation in ALS [6,7,8,9] and can be useful
for detecting patients who need a tracheostomy [7], its diagnostic
power was insufficient for predicting compliance with subsequent
NIV treatment in the present study. This might be because the
main cause of nocturnal respiratory insufficiency in ALS is a
ventilation impairment in which hypercapnea causes hypoxia,
rather than an oxygenation impairment in which hypoxia precedes
hypercapnea [10]. Therefore, measurement of their ventilatory
status with capnography might be more effective in predicting
NIV compliance than measurement of oxygenation status with
pulse oximetry, as was shown in this study.
Brief waking supine capnography can address the effect of
respiratory muscle weakness and orthopnea, which are supposed
to play an important role in aggravating nocturnal hypoventilation
[27]. This could explain its correlation with nocturnal respiratory
symptoms and signs and its predictive value for good compliance
with subsequent NIV treatment. In addition, it might also imply
that these two factors can play a major role in determining the
compliance with NIV treatment.
Compliance with NIV treatment in patients with ALS can be
influenced by various factors, such as signs or symptoms of
nocturnal hypoventilation, and the presence of bulbar symptoms
[3,8]. We assessed both the need for NIV (orthopnea-
questionnaire scores, nocturnal hypercapnea, and nocturnal
hypoxia) and treatment obstacles (ALSFRSr scores for speech,
salivation, and swallowing). However, only the severity of
hypercapnea as measured by capnography had a good predictive
value for subsequent NIV compliance (Table 2). Our results
suggest that the need for NIV in patients with ALS is more of an
influence than an obstacle for compliance with subsequent NIV
treatment.
The mean compliance to subsequent NIV in our study is
relatively low (mean: 4.74 hours/day, ranged 0–10). This seems
largely because patients who complain subjective orthopnea/
dyspnea but who didn’t have objective signs of nocturnal
hypoventilation were also included. The significantly longer
duration of nocturnal hypercapnea in good compliance group
(n=14), than that in poor compliance group (n=6)
(28.27637.85% vs 0.1760.41% respectively, p=0.016) in this
study also support our hypothesis for this phenomenon.
Our study was subject to a few limitations. First, our patient
population was small. Second, we chose a BiPAP ventilator as a
standard NIV treatment. This particular instrument was the only
small portable NIV aid available in our clinic at the beginning of
this study. Whether such instruments are adequate for patients
with neuromuscular disease remains a matter of debate due to
their variable ability to maintain lung compliance and provocation
of coughing [28]. However, a recent randomized controlled study
found that pressure and volume ventilators are equivalent in terms
of their effects on physiology, function, and quality of life [29].
Third, the majority of patients enrolled in this study had relatively
well preserved pulmonary function and were in their early stage of
disease.(mean vital capacity was 57.19% of normal and mean
ALSFRSr was 32.0) Our result may not be extrapolated to patients
with ALS in more advanced stage of disease. Finally, we used
ETCO2 to indirectly monitor nocturnal PaCO2, which has some
inherent limited clinical indications (as described above) and
prevented us from monitoring one of our patients with severe
bulbar dysfunction and subsequent mouth breathing. tcCO2 may
have been applicable to more patients.
In conclusion, we have shown that in selected patients with
ALS, both nocturnal and brief waking supine capnography can
play important roles in assessing nocturnal hypoventilation and
can have a higher diagnostic value in predicting good compliers to
subsequent NIV treatment than conventional pulse oximetry
monitoring or assessment of subjective symptoms. Capnography
can thus be useful as an adjunctive tool for assessing the need for
NIV in patients with ALS.
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Figure S1 Receiver operating characteristic (ROC)
curve for duration of hypoxia (arterial oxygen satura-
tion, SaO2,95%), average nocturnal SaO2 level (avr
SaO2), bulbar function (bulbar scores), and symptoms
for nocturnal hypoventilation (orthopnea) as predictors
of good compliance with subsequent noninvasive venti-
lation treatment.
(TIF)
Table S1 Sensitivities and specificities of nocturnal
capnography, pulse oximetry, and scores from the
orthopnea and bulbar function questionnaire in Amyo-
trophic Lateral Sclerosis Functional Rating Scale –
Revised (ALSFRSr) for predicting good compliance with
subsequent noninvasive ventilation (NIV) treatment are
listed according to their cut-off values. ETCO2, end-tidal
carbon dioxide; avr, average; SaO2, arterial oxygen saturation.
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Table S2 Sensitivities and specificities of waking cap-
nography and pulse oximetry for predicting good
compliance with following NIV treatment are listed
according to their cut-off values.
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